Correction: A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy

Dipankar Pramanik¹,²,^*, Nathaniel R. Campbell¹,²,^*, Samarjit Das², Sonal Gupta¹,², Venugopal Chenna¹,², Savita Bisht⁵, Polina Sysa-Shah³, Djahida Bedja³, Collins Karikari¹,², Charles Steenbergen², Kathleen L. Gabrielson³, Amarnath Maitra⁶, Anirban Maitra¹,²,⁴

¹The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
²Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
³Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
⁴Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
⁵Department of Internal Medicine 3, Center of Integrated Oncology Cologne-Bonn, University of Bonn, Germany
⁶Senior Scientist, Indian National Science Academy, New Delhi, India. π Deceased
^*Constitutes equal contribution

Published: April 24, 2026

This article has been corrected:This article has been corrected: It was noted that the immunofluorescence image for ‘NanoDox’ (ND) in Figure 2C was incorrectly selected, resulting in identical images being shown for both the vehicle (Veh) and ND post-treatment levels of MDR1 expression in RPMI8226/Dox xenografts.

The authors have provided a corrected Figure 2C using the original image for the ND post-treatment level of MDR1 expression. The replacement of this image does not alter the study’s conclusions. The authors sincerely apologize for any inconvenience this may cause to readers.

Original article: Oncotarget. 2012; 3:640-650. DOI: https://doi.org/10.18632/oncotarget.543.

Figure 2: NDC overcomes DOX resistance in vivo. (A) Representative tumor sections from RPMI8226/Dox xenografts were examined by fluorescence microscopy for nuclear accumulation of DOX by doxorubicin fluorescence. (B) NDC significantly inhibits the growth of subcutaneous DOX-resistant cancer xenografts PC-3A and RPMI8226/Dox. Representative excised xenograft tumors from each of the four arms are illustrated. NDC significantly blocked tumor growth compared to either ND or NC (N = 5, *p < 0.005). Post treatment levels of MDR1 expression were measured by (C) immunofluorescence and (D) western blot in RPMI8226/Dox xenografts. (E) BDF1 mice bearing P388/ADR DOX-resistant ascites were treated with vehicle, ND, or NDC. A greater than 50% increase in survival was observed in NDC treated mice compared to ND or vehicle treated mice (N = 8, *p < 0.005).